Article (Scientific journals)
A critical review of ustekinumab for the treatment of active ulcerative colitis in adults.
Vieujean, Sophie; Louis, Edouard; Danese, Silvio et al.
2023In Expert Review of Gastroenterology and Hepatology, p. 1 - 18
Peer Reviewed verified by ORBi
 

Files


Full Text
A_critical_review_of_ustekinumab_for_the_treatment_of_active_ulcerative_colitis_in_adults_revised.docx
Author preprint (451.05 kB)
Request a copy

All documents in ORBi are protected by a user license.

Send to



Details



Keywords :
Ustekinumab; efficacy; real-world studies; safety; ulcerative colitis
Abstract :
[en] INTRODUCTION: Ustekinumab is a humanized monoclonal antibody, targeting the p40 subunit common to both human interleukin 12 and 23, approved by the European Medicines Agency and US Food and Drug Administration for the treatment of moderate-to-severe ulcerative colitis. AREAS COVERED: In this review, the results of the phase 3 UNIFI and the real-world studies assessing the efficacy and safety of ustekinumab in moderate-to-severe ulcerative colitis are discussed, as well as limitations of these studies. Predictive factors of response, the interest of therapeutic drug monitoring and the positioning of ustekinumab in specific situations are also addressed. Finally, in the light of data presented, the positioning of ustekinumab in the therapeutic algorithm of ulcerative colitis will also be considered. EXPERT OPINION: Ustekinumab has been shown to be effective to induce and maintain clinical, endoscopic and histologic remission in moderate-to-severe ulcerative colitis both in phase 3 and real-world studies, with a favorable safety profile. Overall, its favorable risk-benefit ratio, its efficacy on extra-intestinal manifestations and in biologics failure patients make ustekinumab an ideal candidate as first, second, or third-line therapy in ulcerative colitis.
Disciplines :
Gastroenterology & hepatology
Author, co-author :
Vieujean, Sophie  ;  Centre Hospitalier Universitaire de Liège - CHU > > Service de gastroentérologie, hépatologie, onco. digestive
Louis, Edouard  ;  Centre Hospitalier Universitaire de Liège - CHU > > Service de gastroentérologie, hépatologie, onco. digestive
Danese, Silvio ;  Department of Gastroenterology and Endoscopy, IRCCS San Raffaele Hospital and Vita-Salute San Raffaele University, Milan, Italy
Peyrin-Biroulet, Laurent;  CHRU-Nancy, Department of Gastroenterology, University of Lorraine, Nancy, France ; Inserm, NGERE, University of Lorraine, Nancy, France
Language :
English
Title :
A critical review of ustekinumab for the treatment of active ulcerative colitis in adults.
Publication date :
26 March 2023
Journal title :
Expert Review of Gastroenterology and Hepatology
ISSN :
1747-4124
eISSN :
1747-4132
Publisher :
Taylor and Francis Ltd., England
Pages :
1 - 18
Peer reviewed :
Peer Reviewed verified by ORBi
Funding text :
The ability of ustekinumab to improve the clinic, endoscopy and histology of UC patients was supported by biomarkers improvement. Biochemical remission was achieved in 14% at the end of induction in the study of Thunberg et al. (without significant decrease of fecal calprotectin) and 32% at long term []. A significant decrease in CRP and fecal calprotectin in response to ustekinumab treatment has been reported in several studies [,,,].
Available on ORBi :
since 17 April 2023

Statistics


Number of views
61 (4 by ULiège)
Number of downloads
2 (2 by ULiège)

Scopus citations®
 
2
Scopus citations®
without self-citations
2
OpenCitations
 
0

Bibliography


Similar publications



Contact ORBi